GlobeNewsWire
21 May 2026, 21:00 UTC · 25w ago
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Impact · against what's priced in
The preliminary Phase 1 data for OP-3136 provides a positive catalyst by demonstrating anti-tumor activity in over two-thirds of patients and manageable safety, adding a new value driver to the pipeline. While the OPERA-02 update is a key milestone, a 'trial-in-progress' poster provides limited new data compared to the OP-3136 efficacy results.
- OLMA+0.60
No priced-in read yet





